Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.

Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, Campion J, Endermann T, Takahashi K, Saito Y, Catena R, Schomburg L, Calvo A.

Prostate. 2011 Jun 1;71(8):824-34. doi: 10.1002/pros.21298. Epub 2010 Nov 17.

PMID:
21456065
2.
3.

Down-regulation of drs mRNA in human prostate carcinomas.

Kim CJ, Shimakage M, Kushima R, Mukaisho K, Shinka T, Okada Y, Inoue H.

Hum Pathol. 2003 Jul;34(7):654-7.

PMID:
12874760
4.

Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.

Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, Anderson C, Johnstone P, Petros JA, Marshall FF, Zhau HE, Chung LW.

Cancer Res. 2006 Oct 1;66(19):9519-26.

5.

Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies.

Lin H, Lu JP, Laflamme P, Qiao S, Shayegan B, Bryskin I, Monardo L, Wilson BC, Singh G, Pinthus JH.

Int J Oncol. 2010 Oct;37(4):761-6.

PMID:
20811696
6.
7.

Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma.

Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR, Habib FK.

Clin Cancer Res. 1999 Mar;5(3):569-76.

8.

Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.

Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, Zhau HE, Chung LW.

Prostate. 2007 May 15;67(7):722-31.

PMID:
17342749
9.

Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype.

Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK.

Cancer Res. 2008 Mar 15;68(6):1777-85. doi: 10.1158/0008-5472.CAN-07-5259.

10.

JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.

Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G.

Prostate. 2008 Jun 15;68(9):924-34. doi: 10.1002/pros.20737.

PMID:
18386285
11.

Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs.

Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y.

Cancer Res. 2004 Sep 1;64(17):5963-72.

12.

MT1G hypermethylation is associated with higher tumor stage in prostate cancer.

Henrique R, Jerónimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1274-8.

13.

Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.

Ripple MO, Henry WF, Rago RP, Wilding G.

J Natl Cancer Inst. 1997 Jan 1;89(1):40-8.

PMID:
8978405
14.

Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer.

Barbisan F, Mazzucchelli R, Santinelli A, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R.

Histopathology. 2010 Oct;57(4):572-9. doi: 10.1111/j.1365-2559.2010.03666.x.

PMID:
20955382
15.

Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer.

Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD.

Cancer. 2000 Jul 1;89(1):123-34.

PMID:
10897009
16.

Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis.

Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C.

Cancer Res. 2005 Aug 1;65(15):6773-9.

17.
18.

INSL3 in the benign hyperplastic and neoplastic human prostate gland.

Klonisch T, Müller-Huesmann H, Riedel M, Kehlen A, Bialek J, Radestock Y, Holzhausen HJ, Steger K, Ludwig M, Weidner W, Hoang-Vu C, Hombach-Klonisch S.

Int J Oncol. 2005 Aug;27(2):307-15.

PMID:
16010410
19.

Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.

Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC.

Clin Cancer Res. 2009 Jul 1;15(13):4322-35. doi: 10.1158/1078-0432.CCR-08-3157. Epub 2009 Jun 9.

20.

SmgGDS is up-regulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells.

Zhi H, Yang XJ, Kuhnmuench J, Berg T, Thill R, Yang H, See WA, Becker CG, Williams CL, Li R.

J Pathol. 2009 Feb;217(3):389-97. doi: 10.1002/path.2456.

PMID:
18973191

Supplemental Content

Support Center